Partition Bio is a biotechnology company that focuses on developing technologies related to membraneless organelles (MLOs) for cellular physiology and organization. The company aims to apply their understanding of LLPS (Liquid-Liquid Phase Separation) to address dysfunctions associated with MLOs, including neurodegenerative diseases, cancers, and viral infections.

PartitionBio Ltd

Partition Bio

PartitionBio  
Exploiting a novel proprietary technology platform to develop biomolecular tools for the use in therapeutic and synthetic biology applications.

contact@partitionbio.co.uk

𝐏𝐚𝐫𝐭𝐢𝐭𝐢𝐨𝐧𝐁𝐢𝐨 𝐚𝐰𝐚𝐫𝐝𝐞𝐝 𝐠𝐫𝐚𝐧𝐭 𝐭𝐨 𝐞𝐱𝐩𝐥𝐨𝐢𝐭 𝐢𝐭𝐬 𝐧𝐨𝐯𝐞𝐥 𝐛𝐢𝐨𝐥𝐨𝐠𝐢𝐜𝐬 𝐬𝐡𝐮𝐭𝐭𝐥𝐞 𝐩𝐥𝐚𝐭𝐟𝐨𝐫𝐦 𝐟𝐨𝐫 𝐭𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜 𝐧𝐮𝐜𝐥𝐞𝐢𝐜 𝐚𝐜𝐢𝐝𝐬 𝐝𝐞𝐥𝐢𝐯𝐞𝐫𝐲 
PartitionBio received a grant from the Bill & Melinda Gates Foundation to utilise its proprietary biocondensate-based macromolecule delivery platform for the transfection of cells with nucleic acids. The purpose of the project is to deploy the breakthrough technology as a novel non-viral tool for the introduction of protein-encoding RNA or DNA into human cells. The long-term aim of the work is to enable a more efficient approach for the expression of therapeutic proteins in patients.


𝐀𝐛𝐨𝐮𝐭 𝐏𝐚𝐫𝐭𝐢𝐭𝐢𝐨𝐧𝐁𝐢𝐨
PartitionBio is a Cambridge (UK) based biotech start-up company offering a revolutionary technology platform for the non-viral delivery of a broad spectrum of macromolecules with therapeutic potential across the cell membrane. Possible payloads for the shuttle condensates include antibodies, proteins, peptides and nucleic acids.

CO

UK:CO:PARTITIONBIO

Partition Bio

locale

market

industry

website

linkedin

investor of

Metrics